Lewis Karen 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 14, 2025
Insider Transaction Report
Form 4
Lewis Karen
Chief People Officer
Transactions
- Sale
Common Stock
2025-01-13$28.70/sh−1,599$45,895→ 45,099 total
Footnotes (2)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 10, 2025.
- [F2]This includes 116 shares from April 30, 2024 ESPP purchase and 195 shares from the October 31, 2024 ESPP purchase.